Introduction
============

Esophageal carcinoma is one of the leading causes of cancer-related death worldwide, especially in Asia.[@b1-ott-10-3965] Most Asian patients are diagnosed as having esophageal squamous cell carcinoma (ESCC), and the histology is somewhat different from non-Asian populations.[@b2-ott-10-3965],[@b3-ott-10-3965] Despite timely surgical interventions at an early stage, many cases tend to recur during the follow-ups.[@b4-ott-10-3965],[@b5-ott-10-3965] Currently, platinum-based regimens are a standard first-line treatment for advanced ESCC with a median progression-free survival (PFS) under 6 months.[@b6-ott-10-3965] No definitive chemotherapeutic regimen has been properly established for those who have failed prior first-line chemotherapy.

Vascular endothelial growth factor (VEGF) could stimulate the growth of new blood vessels, regulate vascular permeability and exert anti-apoptotic effects in endothelial cells. It frequently becomes overexpressed in esophageal cancers.[@b7-ott-10-3965],[@b8-ott-10-3965] In addition, its overexpression was identified as a poor prognostic predictor for advanced ESCC.[@b9-ott-10-3965]

Previous studies have indicated that apatinib, a VEGFR-2 inhibitor, was potentially efficacious for solid carcinomas.[@b10-ott-10-3965] As a small-molecule, VEGFR tyrosine kinase inhibitor improved PFS and overall survival (OS) in pretreated patients with advanced gastric cancer.[@b11-ott-10-3965],[@b12-ott-10-3965] However, no clinical studies have examined the efficacy and safety of apatinib treatment for advanced ESCC.

A retrospective study was conducted to evaluate the efficacy and safety of apatinib for advanced ESCC after failed prior first-/further-line treatment.

Patients and methods
====================

Patient eligibility
-------------------

Patients with advanced ESCC receiving apatinib as second/further-line treatment between March 2014 and June 2016 were included. All histological diagnoses of ESCC were made according to the histopathological criteria of WHO 2015 version. No local radiotherapy or interventional therapy was offered during apatinib dosing. The study protocol was approved by our institutional review board of Zhejiang Cancer Hospital. All participants provided informed consent prior to treatment.

Treatment regimen
-----------------

Apatinib was administered at a daily dose of 500 mg, and one treatment cycle lasted 28 days. In addition, one dose reduction (500--250 mg) was allowed for drug-related toxicity.

Responses and toxicities
------------------------

Tumor efficacy was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Objective tumor responses included complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). In addition, toxicities were assessed by the National Cancer Institute Common Toxicity Criteria version 4.0 (CTC 4.0). Tumor responses were evaluated for every two cycles when no noticeable sign of progression was present.

Follow-ups and statistical analyses
-----------------------------------

PFS denoted the time from the first dosing day of apatinib to documented progression or mortality from any cause. In addition, OS was defined as the time from the first dosing day to mortality or the last follow-up. Survival analysis was conducted using the Kaplan--Meier method and compared using log-rank test. The survival curves were plotted according to the Kaplan--Meier method. Statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). The median follow-up period was 10.2 (2.0--22) months. Follow-ups were conducted up to October 30, 2016.

Results
=======

Patient characteristics
-----------------------

A total of 62 patients diagnosed with ESCC were included in the current study. Among them, 54 were male and eight were female with a median age of 60.5 years. In addition, 46 of them were previous or current smokers and 16 belonged to never smoker category. All of them received platinum-based first-line chemotherapy. Apatinib was prescribed as second-line (n=21) and further-line (n=41) treatments. Performance status (PS) was 0--1 in 52 patients and 2 in 10 patients. Patient characteristics are summarized in [Table 1](#t1-ott-10-3965){ref-type="table"}.

Clinical efficacies
-------------------

The clinical responses were as follows: CR (n=0), PR (n=15), SD (n=31) and PD (n=16). The values of objective response rate (ORR) and disease control rate (DCR) were 24.2% and 74.2%, respectively. The median PFS was 115 days (95% CI, 97--133; [Figure 1](#f1-ott-10-3965){ref-type="fig"}), and the median OS was 209 days (95% CI, 165--253; [Figure 2](#f2-ott-10-3965){ref-type="fig"}).

No significant correlation existed in PFS among gender (*P*=0.51), age (*P*=0.43), line of therapy (*P*=0.43), smoking history (*P*=0.23), location of tumor (*P*=0.44) and PS (*P*=0.06). Univariate analysis is detailed in [Table 2](#t2-ott-10-3965){ref-type="table"}. Patients with grade 3/4 toxicities showed a longer PFS than those without grade 3/4 toxicity (136 vs 63 days, *P*=0.044; [Figure 3](#f3-ott-10-3965){ref-type="fig"}). Interestingly, PFS in individuals with grade 3/4 hypertension and hand-foot syndrome was longer than that in other patients (153 vs 112 days, *P*=0.037).

Among 46 SD patients, 13 had a PFS of \>6 months, and the patient characteristics are summarized in [Table 3](#t3-ott-10-3965){ref-type="table"}.

Toxicity evaluations
--------------------

The median dose of apatinib was 500 (250--500) mg. Ten dosage reductions were available. The rate of grade 3/4 toxicities was 59.7% (37/62). Five patients presented with grade 4 toxicity, including worsening proteinuria (n=2), hypertension (n=2) and hand-foot syndrome (n=1). The most common grade 3/4 adverse events were as follows: hand-foot syndrome (n=10), hypertension (n=7), proteinuria (n=7), hepatic injury (n=5), fatigue (n=3), esophagitis (n=3) and nausea/vomiting (n=2; [Table 4](#t4-ott-10-3965){ref-type="table"}).

Discussion
==========

To sum up, apatinib had some potential efficacy as a salvage treatment for advanced ESCC therapy. To the best of our knowledge, it represented the first-ever attempt of examining the efficacy and safety of apatinib for advanced ESCC.

Platinum-based agents are currently a standard first-line treatment for advanced ESCC, and the median PFS has a range of 4--6 months.[@b13-ott-10-3965]--[@b15-ott-10-3965] Half of the patients unresponsive to first-line treatment might receive a second-line therapy. Yet, the median PFS remains at a range of 2--4 months.[@b16-ott-10-3965],[@b17-ott-10-3965] For patients who have failed second-line chemotherapy, no definitive chemotherapeutic regimen has been recommended. New treatment strategy is urgently needed for achieving a better PS.

Several studies have identified the blockage of VEGFR-2 as a promising therapy for inhibiting angiogenesis.[@b18-ott-10-3965],[@b19-ott-10-3965] Apatinib, the first oral VEGFR-2 inhibitor, has previously demonstrated survival benefits for metastatic gastric cancer.[@b12-ott-10-3965] Although approved domestically for gastric cancer treatment, apatinib was also effective for patients with advanced breast carcinoma and lung cancer who are unresponsive to standard pretreatment.[@b20-ott-10-3965],[@b21-ott-10-3965] In the current study, the values of DCR and ORR were 74.2% and 24.2%, respectively. There was a trend of better efficacy compared with second-line chemotherapy for advanced ESCC.[@b5-ott-10-3965] Interestingly, patients with grade 3/4 toxicities had a longer PFS than those without grade 3/4 toxicities. Patients with hypertension and hand-foot syndrome benefited more than those with other adverse events. Together with previous study,[@b12-ott-10-3965] our results indicated that some toxicities would be predictive factors for the efficacy of apatinib treatment.

Hand-foot skin reaction, proteinuria and hypertension were the most common adverse events in apatinib treatment, with grade 3/4 adverse events occurring in over 60% of patients with gastric carcinoma.[@b11-ott-10-3965],[@b12-ott-10-3965] Over 20% of patients experienced dose modifications with a recommended daily dose of apatinib (850 mg) treatment in a Phase III trial.[@b12-ott-10-3965] In another trial, the recommended daily dose was 500 mg and grade 3/4 toxicities significantly decreased, and the efficacy was similar to those of high dose for breast carcinoma.[@b20-ott-10-3965] In the current study, a recommended dose of 500 mg was used. The results showed that grade 3/4 toxicities occurred in over half of the patients. Although different daily apatinib doses were used for gastric carcinoma (850 mg) and breast carcinoma (500 mg), similar toxicities were observed. It was considered that several patients with gastric carcinoma underwent previous gastrectomy, and the absorption ability of apatinib might be lowered.

Retrospective nature and a small sample size were two major limitations of the current study. In addition, the dose of 500 mg apatinib adopted in this study was not widely recommended. Hence, this dose must be confirmed by further prospective studies. However, without prospective clinical studies in the literature, our study may be deemed as meaningful.

Conclusion
==========

Our results support that apatinib is efficacious for advanced ESCC as salvage treatment. However, further prospective studies are required to fully elucidate its efficacy and toxicity.
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###### 

Clinical characteristics of 62 patients

  Variables                                 N (%)
  ----------------------------------------- ---------------
  Gender                                    
   Male                                     54 (87.1)
   Female                                   8 (12.9)
  Age (years)                               
   Median (range)                           60.5 (40--72)
   \>60                                     32 (51.6)
   ≤60                                      30 (48.4)
  PS                                        
   0--1                                     52 (83.9)
   2                                        10 (16.1)
  Smoking history                           
   Yes                                      46 (74.2)
   No                                       16 (25.8)
  Alcohol use                               
   Yes                                      49 (79.0)
   No                                       13 (21.0)
  Location of tumor                         
   Upper third                              9 (14.5)
   Middle third                             24 (38.7)
   Lower third                              29 (46.8)
  Line of apatinib therapy                  
   Second                                   21 (33.9)
   Further                                  41 (66.1)
  Prior therapies in advanced stage         
   Chemotherapy                             44 (71.0)
   Chemoradiotherapy                        18 (29.0)
  Post-progression therapy after apatinib   
   Chemotherapy                             16 (25.8)
   Palliative treatment                     46 (74.2)

**Abbreviation:** PS, performance status.

###### 

Univariate analysis of the current population (n=62)

  Characteristics           PFS   95% CI     *P*-value   OS    95% CI     *P*-value
  ------------------------- ----- ---------- ----------- ----- ---------- -----------
  Gender                                     0.51                         0.24
   Male                     95    72--125                176   165--256   
   Female                   122   87--142                234   199--277   
  Age (years)                                0.43                         0.34
   \>60                     110   107--133               231   168--266   
   ≤60                      117   87--121                201   176--254   
  PS                                         0.06                         0.04
   0--1                     132   106--157               254   226--312   
   2                        87    55--125                156   117--204   
  Line of therapy                            0.43                         0.45
   Second                   126   75--131                234   176--265   
   Further                  111   87--129                199   167--254   
  Smoking history                            0.23                         0.55
   Yes                      98    67--119                204   187--255   
   No                       124   89--132                255   211--269   
  Location of tumor                          0.44                         0.25
   Upper and middle third   101   78--125                187   167--254   
   Lower third              117   111--135               231   207--288   

**Abbreviations:** OS, overall survival; PFS, progression-free survival; PS, performance status.

###### 

Clinical profile of patients with PFS \>6 months

  Case   Gender   Age (years)   Smoking   Line of therapy   Grade 3/4 toxicity   PFS (days)   OS (days)
  ------ -------- ------------- --------- ----------------- -------------------- ------------ -----------
  1      Male     56            Yes       Second            Yes                  188          252
  2      Male     63            Yes       Third             Yes                  181          254
  3      Male     64            No        Second            Yes                  195          357+
  4      Female   54            No        Fifth             No                   251          661
  5      Male     65            Yes       Second            Yes                  304          564
  6      Female   48            No        Fifth             No                   189          216
  7      Male     63            Yes       Third             Yes                  242          458
  8      Male     64            No        Second            Yes                  511          583
  9      Female   62            No        Second            Yes                  251          279
  10     Female   54            No        Third             No                   274          348
  11     Male     57            Yes       Third             Yes                  191          303
  12     Male     54            Yes       Second            No                   182          191
  13     Male     50            Yes       Fourth            No                   211          351

**Abbreviations:** OS, overall survival; PFS, progression-free survival.

###### 

Major toxicities of apatinib dosing

  Toxicity             Total (%)   Grades 3/4 (%)   Dosage reduction (%)   Discontinuation (%)
  -------------------- ----------- ---------------- ---------------------- ---------------------
  Hand-foot syndrome   32 (51.6)   10 (16.1)        2 (20.0)               1 (33.3)
  Hypertension         13 (21.0)   7 (11.3)         2 (20.0)               1 (33.3)
  Proteinuria          15 (24.2)   7 (11.3)         2 (20.0)               1 (33.3)
  Hepatic injury       12 (19.4)   5 (8.1)          0 (0.0)                0 (0.0)
  Fatigue              9 (14.5)    3 (4.8)          2 (20.0)               0 (0.0)
  Esophagitis          4 (6.5)     3 (4.8)          2 (20.0)               0 (0.0)
  Nausea/vomiting      9 (14.5)    2 (4.8)          0 (0.0)                0 (0.0)
